Bin Liu, PhD
Languages
Education
Fellowship
Degrees
Contact Information
Scientific Interests
Dr. Bin Liu's research is primarily focused on developing novel targeted and immunotherapies for non-small cell lung cancer (NSCLC), including small molecule inhibitors targeting non-mutation driven cancer dependencies, as well as cellular therapies with cytokine gene-modified dendritic cells and CAR-engineered natural killer cells. Dr. Liu's research interests include elucidating mechanisms of action, understanding the development of immune evasion, and identifying potential biomarkers of response vs. resistance to these therapeutic strategies, utilizing both patient biospecimens and disease-relevant murine models of NSCLC.
Highlighted Publications
Salehi-Rad R, Li R, Tran LM, Lim RJ, Abascal J, Momcilovic M, Park SJ, Ong SL, Shabihkhani M, Huang ZL, Paul M, Shackelford DB, Krysan K, Liu B*, Dubinett SM*. Novel Kras-mutant murine models of non-small cell lung cancer possessing co-occurring oncogenic mutations and increased tumor mutational burden. Cancer Immunol Immunother. 2021 Jan 28;. doi: 10.1007/s00262-020-02837-9. PubMed PMID: 33507343. (*Co-corresponding author)
Li R, Salehi-Rad R, Crosson W, Momcilovic M, Lim RJ, Ong SL, Huang ZL, Zhang T, Abascal J, Dumitras C, Jing Z, Park SJ, Krysan K, Shackelford DB, Tran LM, Liu B*, Dubinett SM*. Inhibition of Granulocytic Myeloid-Derived Suppressor Cells Overcomes Resistance to Immune Checkpoint Inhibition in LKB1-deficient Non-Small Cell Lung Cancer. Cancer Res. 2021 Apr 14;. doi: 10.1158/0008-5472.CAN-20-3564. PubMed PMID: 33853830. (*Cocorresponding author)
Saggese P, Martinez CA, Tran LM, Lim R, Dumitras C, Grogan T, Elashoff D, Ramin SR, Dubinett SM, Liu B, Scafoglio C. Genotoxic Treatment Enhances Immune Response in a Genetic Model of Lung Cancer. Cancers (Basel). 2021 Jul 18;13(14):3595. doi: 10.3390/cancers13143595. PMID: 34298808; PMCID: PMC8307650.
Salehi-Rad R, Lim RJ, Du Y, Tran LM, Li R, Ong SL, Huang ZL, Dumitras C, Zhang T, Park SJ, Crosson W, Kahangi B, Abascal J, Christopher Seet C, Oh M, Shabihkhani M, Paul M, Krysan K, Lisberg A, Garon EB, Liu B*, Dubinett SM*. CCL21-DC in situ vaccination in murine NSCLC overcomes resistance to immunotherapy and generates systemic tumor-specific immunity. J of ImmunoTherapy of Cancer. 2023 Sep;11(9):e006896. (*Co corresponding author).
Abascal J, Oh MS, Liclican EL, Dubinett SM, Salehi-Rad R*, Liu B*. Dendritic cell vaccination in non-small cell lung cancer: Remodeling the tumor immune microenvironment. Cells 2023, 12, 2404. (*Co-corresponding author)
